my personal edition > renal failure > news


  E-Mail this DGNews to a colleague

DGNews

Vitamin D Linked to Reduced Mortality Rate in Chronic Kidney Disease

Washington, DC -- May 7, 2008 -- For patients with moderate to severe chronic kidney disease (CKD), treatment with activated vitamin D may reduce the risk of death by approximately one-fourth, suggests a study in the August issue of the Journal of the American Society of Nephrology.

Many patients with advanced CKD take the drug calcitriol to treat elevated levels of parathyroid hormone. "Although activated vitamin D is known to influence many biological processes, previous clinical knowledge is limited to its effect on parathyroid hormone levels," explains study coauthor Bryan Kestenbaum, MD, MS, Assistant Professor of Medicine, Division of Nephrology, University of Washington School of Medicine, Seattle, Washington, one of the study authors.

The study included 1,418 patients with stage 3 to 4 CKD. All patients also had hyperparathyroidism, which can contribute to weakening of the bones in CKD. The researchers identified 1 group of patients who were being treated with calcitriol to lower their parathyroid hormone levels and another group who were not receiving calcitriol.

During a 2-year follow-up period, mortality rates were compared for patients who were and were not taking calcitriol. "We then adjusted for differences in age, kidney function, parathyroid hormone levels, other illnesses, and other medications," says Dr. Kestenbaum.

In the adjusted analysis, the overall risk of death was about 26% lower for patients taking calcitriol. Patients on calcitriol were also less likely to develop end-stage renal disease, requiring dialysis to replace lost kidney function.

Overall, treatment with calcitriol was associated with a 20% reduction in the risk of either death or dialysis. The reduction in mortality with calcitriol was unrelated to its effect on parathyroid hormone levels.

"Recently, there has been an increased focus on the effects of vitamin D beyond those on bone health," Dr. Kestenbaum comments. "Vitamin D deficiency has been associated with risk factors for cardiovascular disease, such as high blood pressure; diabetes; and inflammation." Previous studies have suggested that treatment with intravenous vitamin D can improve survival in patients on haemodialysis.

The new results suggest that treatment with oral activated vitamin D may also improve survival in patients with CKD who do not yet require dialysis. "Randomised clinical trials are needed to test the hypothesis that vitamin D therapy can improve cardiovascular health and survival in CKD," Dr. Kestenbaum adds. "Future studies should also examine the role of nonactivated vitamin D, which is less expensive and less toxic."

The study has some important limitations, including a lack of data on other factors that may have affected survival in patients taking calcitriol. Also, since the study included mainly older, white men, the results may not apply to younger, more ethnically diverse populations with CKD.

This study was supported by a Career Development Award from the National Institutes of Health. Dr. Kestenbaum receives consulting fees from Abbott and Shire as well as grant support from Amgen.

SOURCE: American Society of Nephrology

E-Mail this DGNews to a colleague

To print, use this version